We investigated the specific ALDH1A1 inhibitors, NCT-505 and NCT-506, that were previously developed and tested on ovarian cancer cell lines and were shown to sensitize paclitaxel-resistant ovarian cancer cells (20). Here, ALDH1A1 is linked to ovarian carcinoma.